Assertio Therapeutics Inc (ASRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) has a cash flow conversion efficiency ratio of 0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.56 Million) by net assets ($75.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Assertio Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Assertio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Assertio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Assertio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assertio Therapeutics Inc ranked by their cash flow conversion efficiency. Explore ASRT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inission AB (publ)
ST:INISS-B
|
0.058x |
|
Koenig & Bauer AG
XETRA:SKB
|
0.098x |
|
Daedong Ind
KO:000490
|
-0.033x |
|
Athens Medical C.S.A.
AT:IATR
|
0.029x |
|
Hanmiglobal
KO:053690
|
-0.005x |
|
Texaf SA
BR:TEXF
|
0.017x |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
0.076x |
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Assertio Therapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Assertio Therapeutics Inc from 1996 to 2025. View Assertio Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $93.95 Million | $-28.18 Million | -0.300x | -237.53% |
| 2024-12-31 | $121.08 Million | $26.41 Million | 0.218x | -39.32% |
| 2023-12-31 | $138.00 Million | $49.60 Million | 0.359x | +3.23% |
| 2022-12-31 | $225.72 Million | $78.60 Million | 0.348x | +545.68% |
| 2021-12-31 | $102.41 Million | $5.52 Million | 0.054x | +104.57% |
| 2020-12-31 | $55.51 Million | $-65.57 Million | -1.181x | -175.67% |
| 2019-12-31 | $57.96 Million | $90.47 Million | 1.561x | +374.44% |
| 2018-12-31 | $220.34 Million | $72.50 Million | 0.329x | -10.28% |
| 2017-12-31 | $169.51 Million | $62.17 Million | 0.367x | +40.42% |
| 2016-12-31 | $250.79 Million | $65.50 Million | 0.261x | -42.81% |
| 2015-12-31 | $315.06 Million | $143.89 Million | 0.457x | +397.67% |
| 2014-12-31 | $364.45 Million | $-55.92 Million | -0.153x | -316.15% |
| 2013-12-31 | $137.42 Million | $9.75 Million | 0.071x | +119.23% |
| 2012-12-31 | $83.94 Million | $-30.98 Million | -0.369x | -167.82% |
| 2011-12-31 | $105.92 Million | $57.65 Million | 0.544x | +628.20% |
| 2010-12-31 | $23.11 Million | $-2.38 Million | -0.103x | -188.17% |
| 2009-12-31 | $15.73 Million | $1.84 Million | 0.117x | +15.63% |
| 2008-12-31 | $33.15 Million | $3.35 Million | 0.101x | -68.62% |
| 2007-12-31 | $45.52 Million | $14.66 Million | 0.322x | -68.27% |
| 2006-12-31 | $-27.29 Million | $-27.70 Million | 1.015x | -76.18% |
| 2005-12-31 | $6.76 Million | $28.82 Million | 4.262x | +253.93% |
| 2004-12-31 | $8.40 Million | $-23.27 Million | -2.769x | -188.82% |
| 2003-12-31 | $34.58 Million | $-33.15 Million | -0.959x | -238.57% |
| 2002-12-31 | $-6.41 Million | $-4.44 Million | 0.692x | -91.76% |
| 2001-12-31 | $-1.48 Million | $-12.40 Million | 8.393x | +678.64% |
| 2000-12-31 | $4.59 Million | $-6.65 Million | -1.451x | -238.96% |
| 1999-12-31 | $9.22 Million | $-3.94 Million | -0.428x | -57.48% |
| 1998-12-31 | $9.20 Million | $-2.50 Million | -0.272x | -1.28% |
| 1997-12-31 | $4.10 Million | $-1.10 Million | -0.268x | -126.83% |
| 1996-12-31 | $-400.00K | $-400.00K | 1.000x | -- |
About Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more